AI Meets Gene Editing: the Path to Plug-and-Play Drug Development
AI is no panacea, but it can have a role in turning artisanal, trial-and-error drug development into a rapid, cost-effective, data-driven process.
presented by
Using RWD to Improve Clinical Trial Recruitment, Endpoints, and Inform Market Access Strategies
The webinar, sponsored by PurpleLab and scheduled for May 22, will explore how healthcare sector companies can leverage real world data (RWD) with a focus on lung cancer.
The Human Algorithm: What AI Can’t Replace in Pharma Engagement
At a time when AI is reshaping pharma, Reverba Global CEO Cheryl Lubbert explained in an interview why empathy, context, and ethics still require a human touch.
Continuous Process Improvement: The Secret to Navigating Early-Phase Drug Development
Deploying a robust continuous improvement methodology is especially beneficial in the earliest phases of drug development. It can help ensure the delivery of high-quality, reliable, timely bioanalytical and clinical data to make informed decisions about either moving on to the next drug development milestone or pivoting to another strategy.
Health Economics and Outcomes Research: Biopharma’s Underappreciated Value Creator
The way ahead for HEOR in biopharma should be built on increasing C-suite visibility and understanding of the value contribution that HEOR makes and demonstrating that a failure to invest in HEOR puts companies at a competitive disadvantage, especially in the face of rising regulatory and payer expectations for evidence.
Radiopharmaceutical Manufacturing: A High-Stakes Race Against Time
From the executive boardrooms of pharma companies to academic research centers, one fact is becoming unmistakably clear: making radiopharmaceuticals is an inherently complex, high-stakes endeavor, and the industry is racing to manage the risks of these perishable therapies before the clock runs out
The Future of Drug Discovery is 3D
Improving the identification and validation of disease-specific drug targets in a cell-type and patient-specific manner early on will not only reduce the failure rate and cost that is so inherent in current drug development processes but also allow the development of more effective precision medicines, improving patient outcomes.
What Are Healthcare Organizations Getting Wrong about Email Security?
A new report by Paubox calls for healthcare IT leaders to dispose of outdated assumptions about email security and address the challenges of evolving cybersecurity threats.
Challenges and Opportunities for Digital Innovation in Clinical Trials
The clinical trial process is complex, long, and always arduous. But the results of the drug development process can be amazing, new, safe, effective, life-changing, and life-enhancing therapies.
Enabling Clinical Trial Innovation Through AI Regulation at FDA
As the FDA stakes its claim as the primary regulator of AI in healthcare, it must navigate the delicate balance between fostering innovation and ensuring safety and responsibility.
How Digitizing Data Collection and Analysis in Biopharma Can Drive Better, Faster Insights
Moving from spreadsheets to automated data collection and processing is far from easy, but it could revolutionize drug development. It’s time for the biopharma industry to embrace end-to-end digitalization.
Navigating What Comes Next for mRNA Therapeutics
The next era for mRNA-based therapeutics and vaccines is here, and it’s time to move from an R&D mindset to a focus on long-term success with mRNA and bringing these innovative therapeutics to patients at scale.
presented by
The 3 Best Options to Buy Telemedicine Carts for Neurology Care
Neurologists and health care practitioners must evolve with the world. Telemedicine carts assist in this evolution by serving as an intermediary between patients and doctors.
The Disconnect between R&D Costs and High Drug Prices
Multiple studies have shown no correlation between R&D costs and the launch price of new drugs though that is an argument often used by drugmakers to prevent a cap on pricing. Still, one way to keep costs low, is for organizations to leverage health technology like AI and improve formulary compliance.
Funding to Improve Drug Availability
Government funding plays a major role in the advancement of drugs, including monoclonal antibodies, which are extremely expensive to produce and can take months to develop.
AI-assisted Drug Development is the Future
A drug development approach that makes use of hybrid AI can de-risk drug development while simultaneously removing other barriers to success. In other words, it has the power to significantly reduce the drug development timeline, and ultimately, save more lives.
Fostering the Next Generation of Antisense Oligonucleotide Therapies
Antisense oligonucleotides (ASOs) have faced their share of challenges, but a combination of research advances and a market ripe for innovation is setting this drug class up for a resurgence. Antisense oligonucleotide (ASO)—a class of drugs that works by targeting RNA to alter gene expression and control aberrant proteins in ways that traditional drugs can’t.
MedCity Pivot Podcast: Tackling Rare Disease With Someone Who Was Touched By It
Rich Horgan believes that there's an alternative path to drug development that can lower costs and the time it takes to bring drugs to market. He is trying to apply it to the field of rare and ultra-rare diseases.